^
    Back
    Association details:
    Biomarker:CEACAM5 positive
    Cancer:Gastric Cancer
    Drug:tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluation of SAR408701 in Patients With Advanced Solid Tumors

    Excerpt:
    ...patients with CRC or with CEACAM5 positive non-squamous NSCLC, small cell lung cancer (SCLC) or gastric carcinoma (including esophago-gastric junction adenocarcinoma of the Siewert types II and III)....
    Trial ID:
    CEACAM5
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Abstract 1688: A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors

    Excerpt:
    SAR408701 in vivo efficacy was evaluated in CRC, lung and gastric patient-derived xenografts (PDXs)….The conjugate was able to elicit strong and specific antitumor efficacy in a number of PDX models representative of the CEACAM5-positive patient population.
    DOI:
    10.1158/1538-7445.AM2015-1688